Literature DB >> 33505435

Deregulation of a Cis-Acting lncRNA in Non-small Cell Lung Cancer May Control HMGA1 Expression.

Greg L Stewart1, Adam P Sage1, Katey S S Enfield1, Erin A Marshall1, David E Cohn1, Wan L Lam1.   

Abstract

BACKGROUND: Long non-coding RNAs (lncRNAs) have long been implicated in cancer-associated phenotypes. Recently, a class of lncRNAs, known as cis-acting, have been shown to regulate the expression of neighboring protein-coding genes and may represent undiscovered therapeutic action points. The chromatin architecture modification gene HMGA1 has recently been described to be aberrantly expressed in lung adenocarcinoma (LUAD). However, the mechanisms mediating the expression of HMGA1 in LUAD remain unknown. Here we investigate the deregulation of a putative cis-acting lncRNA in LUAD, and its effect on the oncogene HMGA1.
METHODS: LncRNA expression was determined from RNA-sequencing data of tumor and matched non-malignant tissues from 36 LUAD patients. Transcripts with significantly deregulated expression were identified and validated in a secondary LUAD RNA-seq dataset (TCGA). SiRNA-mediated knockdown of a candidate cis-acting lncRNA was performed in BEAS-2B cells. Quantitative real-time PCR was used to observe the effects of lncRNA knockdown on the expression of HMGA1.
RESULTS: We identified the lncRNA RP11.513I15.6, which we refer to as HMGA1-lnc, neighboring HMGA1 to be significantly downregulated in both LUAD cohorts. Conversely, we found HMGA1 significantly overexpressed in LUAD and anticorrelated with HMGA1-lnc. In vitro experiments demonstrated siRNA-mediated inhibition of HMGA1-lnc in immortalized non-malignant lung epithelial cells resulted in a significant increase in HMGA1 gene expression.
CONCLUSION: Our results suggest that HMGA1-lnc is a novel cis-acting lncRNA that negatively regulates HMGA1 gene expression in lung cells. Further characterization of this regulatory mechanism may advance our understanding of the maintenance of lung cancer phenotypes and uncover a novel therapeutic intervention point for tumors driven by HMGA1.
Copyright © 2021 Stewart, Sage, Enfield, Marshall, Cohn and Lam.

Entities:  

Keywords:  HMGA1; cis-acting; gene regulation; long non-coding RNA; lung cancer LncRNA-Mediated Control of HMGA1 Expression; non-coding RNA

Year:  2021        PMID: 33505435      PMCID: PMC7831742          DOI: 10.3389/fgene.2020.615378

Source DB:  PubMed          Journal:  Front Genet        ISSN: 1664-8021            Impact factor:   4.599


  31 in total

Review 1.  Driver and passenger mutations in cancer.

Authors:  Julia R Pon; Marco A Marra
Journal:  Annu Rev Pathol       Date:  2014-10-17       Impact factor: 23.472

2.  STAR: ultrafast universal RNA-seq aligner.

Authors:  Alexander Dobin; Carrie A Davis; Felix Schlesinger; Jorg Drenkow; Chris Zaleski; Sonali Jha; Philippe Batut; Mark Chaisson; Thomas R Gingeras
Journal:  Bioinformatics       Date:  2012-10-25       Impact factor: 6.937

3.  Elevated expression of HMGA1 correlates with the malignant status and prognosis of non-small cell lung cancer.

Authors:  Ze Zhang; Quan Wang; Feng Chen; Jun Liu
Journal:  Tumour Biol       Date:  2014-10-25

4.  Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a.

Authors:  Kyoko L Yap; Side Li; Ana M Muñoz-Cabello; Selina Raguz; Lei Zeng; Shiraz Mujtaba; Jesús Gil; Martin J Walsh; Ming-Ming Zhou
Journal:  Mol Cell       Date:  2010-06-11       Impact factor: 17.970

Review 5.  Roles of HMGA proteins in cancer.

Authors:  Alfredo Fusco; Monica Fedele
Journal:  Nat Rev Cancer       Date:  2007-12       Impact factor: 60.716

6.  Association of SIRT1 and HMGA1 expression in non-small cell lung cancer.

Authors:  Shuang-Yan Lin; Fang Peng
Journal:  Oncol Lett       Date:  2015-11-13       Impact factor: 2.967

7.  Two distinct repressive mechanisms for histone 3 lysine 4 methylation through promoting 3'-end antisense transcription.

Authors:  Thanasis Margaritis; Vincent Oreal; Nathalie Brabers; Laetitia Maestroni; Adeline Vitaliano-Prunier; Joris J Benschop; Sander van Hooff; Dik van Leenen; Catherine Dargemont; Vincent Géli; Frank C P Holstege
Journal:  PLoS Genet       Date:  2012-09-20       Impact factor: 5.917

8.  Ensembl 2014.

Authors:  Paul Flicek; M Ridwan Amode; Daniel Barrell; Kathryn Beal; Konstantinos Billis; Simon Brent; Denise Carvalho-Silva; Peter Clapham; Guy Coates; Stephen Fitzgerald; Laurent Gil; Carlos García Girón; Leo Gordon; Thibaut Hourlier; Sarah Hunt; Nathan Johnson; Thomas Juettemann; Andreas K Kähäri; Stephen Keenan; Eugene Kulesha; Fergal J Martin; Thomas Maurel; William M McLaren; Daniel N Murphy; Rishi Nag; Bert Overduin; Miguel Pignatelli; Bethan Pritchard; Emily Pritchard; Harpreet S Riat; Magali Ruffier; Daniel Sheppard; Kieron Taylor; Anja Thormann; Stephen J Trevanion; Alessandro Vullo; Steven P Wilder; Mark Wilson; Amonida Zadissa; Bronwen L Aken; Ewan Birney; Fiona Cunningham; Jennifer Harrow; Javier Herrero; Tim J P Hubbard; Rhoda Kinsella; Matthieu Muffato; Anne Parker; Giulietta Spudich; Andy Yates; Daniel R Zerbino; Stephen M J Searle
Journal:  Nucleic Acids Res       Date:  2013-12-06       Impact factor: 16.971

Review 9.  High mobility group a proteins as tumor markers.

Authors:  Pierlorenzo Pallante; Romina Sepe; Francesca Puca; Alfredo Fusco
Journal:  Front Med (Lausanne)       Date:  2015-03-25

10.  HMGA1 exacerbates tumor growth through regulating the cell cycle and accelerates migration/invasion via targeting miR-221/222 in cervical cancer.

Authors:  Fangfang Fu; Tian Wang; Zhangying Wu; Yourong Feng; Wenwen Wang; Su Zhou; Xiangyi Ma; Shixuan Wang
Journal:  Cell Death Dis       Date:  2018-05-22       Impact factor: 8.469

View more
  1 in total

1.  Antioxidant stress and anticancer activity of peptide‑chelated selenium in vitro.

Authors:  Xian Li; Xianjue Wang; Gang Liu; Yanan Xu; Xinlin Wu; Ru Yi; Feng Jin; Chula Sa; Xiulan Su
Journal:  Int J Mol Med       Date:  2021-06-24       Impact factor: 4.101

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.